Institut Pasteur Korea (IPK) and Kainos Medicine announced their 2016 Drug Discovery project against hepatitis B virus (HBV). The collaboration combines IPK’s basic science research capabilities and cell-based screening technology with Kainos Medicine‘s Medical Chemistry optimization expertise. This project aims to discover novel small-molecules effective against HBV. Research kicked off in Aug 2016 and will take place over the next three years. The strategic partnership is part of a series of collaboration projects supported by the Gyeonggi Provincial Government.
Dr. Marc Windisch, Group Leader, IPK Hepatitis Research Laboratory, says, “In order to keep a step ahead it is important to advance our understanding of HBV and explore new avenues for the development of innovative therapeutic agents. Consequently, IPK will collaborate with Kainos Medicine on the discovery of a Lead compound which potentially could cure the disease.”
Dr. Jaemoon Lee, Vice-president of Bio department, Kainos Medicine says, “A collaboration with IPK is a significant. I expect that we will reach the target to develop a novel HBV therapeutics.”
 
Source: ET NEWS (Sep. 13, 2016)